Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 482 results for learning disabilities

  1. Alcohol-use disorders: diagnosis and management (QS11)

    This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.

  2. Develop case identification tools for common mental health problems:- Develop or adapt reliable and valid tools for the case identification of common mental health problems in people with learning disabilities, for routine use in primary care, social care and education settings.

    case identification of common mental health problems in people with learning disabilities, for routine use in primary care, social care...

  3. Self‑harm (QS34)

    This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.

  4. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  5. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  6. Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)?

    vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)? Any explanatory notes(if...

  7. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

  8. Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

    Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.

  9. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  10. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

  11. Babies, children and young people's experience of healthcare (NG204)

    This guideline describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care. It is recognised that parents and carers play a key role, and where appropriate, we took their views into account when developing the recommendations.

  12. Looked-after children and young people (QS31)

    This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.

  13. Drug use disorders in adults (QS23)

    This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.

  14. Inducing labour (QS60)

    This quality standard covers the induction of labour in hospital outpatient or inpatient settings. It includes advice and care for pregnant women who are considering or having induction of labour. It describes high-quality care in priority areas for improvement.